APRIL 25, 2025
Postponement of the publication of the annual financial statements Biophytis announces the postponement of the publication of its annual financial statements for the year ended
APRIL 22, 2025
Biophytis targets mobility restoration in patients with obesity Biophytis strentghens its position as one of the leading players in preserving muscle function in patients with
APRIL 9, 2025
Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity Biophytis confirms the launch of the Phase 2 OBA clinical study in
MARCH 28, 2025
Biophytis announces the settlement and delivery of its €2.6 million private placement NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA,
MARCH 26, 2025
Biophytis announces the successful completion of a €2,6 million private placement Capital increase of a total amount of approximately €2,6 million in gross proceeds by
MARCH 24, 2025
Biophytis announces new non-clinical data further supporting its mission to pioneer the restoration of mobility in patients with obesity 96% of patients with obesity report
MARCH 17, 2025
Biophytis revolutionizes sarcopenia Biophytis is excited to announce a world premiere: the publication of the Phase 2 clinical trial SARA-INT in the Journal of Cachexia,
MARCH 6, 2025
Biophytis announces its participation to the BIO-Europe Spring 2025 in Milan Biophytis is pleased to announce its participation in BIO-Europe Spring 2025, taking place in
FEBRUARY 25, 2025
Biophytis announces its participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR) Biophytis announces its participation in the International Conference on Frailty
FEBRUARY 11, 2O25
Biophytis unveils its outlook strategies for 2025 Biophytis today unveils its strategic outlook for the year 2025. Biophytis has improved its competitive positioning and fundamentals